| Remdesivir for the treatment of Covid-19 JH Beigel, KM Tomashek, LE Dodd, AK Mehta, BS Zingman, AC Kalil, ... New England Journal of Medicine 383 (19), 1813-1826, 2020 | 6035 | 2020 |
| Remdesivir for the treatment of Covid-19—preliminary report JH Beigel, KM Tomashek, LE Dodd, AK Mehta, BS Zingman, AC Kalil, ... New England Journal of Medicine 383 (19), 1813-1836, 2020 | 2551 | 2020 |
| Baricitinib plus remdesivir for hospitalized adults with Covid-19 AC Kalil, TF Patterson, AK Mehta, KM Tomashek, CR Wolfe, V Ghazaryan, ... New England Journal of Medicine 384 (9), 795-807, 2021 | 1795 | 2021 |
| 2011 update of the drug resistance mutations in HIV-1 VA Johnson, V Calvez, HF Günthard, R Paredes, D Pillay, R Shafer, ... Topics in antiviral medicine 19 (4), 156, 2011 | 1253 | 2011 |
| Early remdesivir to prevent progression to severe Covid-19 in outpatients RL Gottlieb, CE Vaca, R Paredes, J Mera, BJ Webb, G Perez, G Oguchi, ... New England Journal of Medicine 386 (4), 305-315, 2022 | 1085 | 2022 |
| Special contribution 2014 Update of the drug resistance mutations in HIV-1 AM Wensing, V Calvez, HF Günthard, VA Johnson, R Paredes, D Pillay, ... Topics in antiviral medicine 22 (3), 642, 2014 | 1075* | 2014 |
| 2015 update of the drug resistance mutations in HIV-1 AM Wensing, V Calvez, HF Günthard, VA Johnson, R Paredes, D Pillay, ... Top Antivir Med 23 (4), 132-41, 2015 | 1028* | 2015 |
| Special contribution 2014 Update of the drug resistance mutations in HIV-1 AM Wensing, V Calvez, HF Günthard, VA Johnson, R Paredes, D Pillay, ... Topics in antiviral medicine 22 (3), 642, 2014 | 1028* | 2014 |
| HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects M J Buzón, M Massanella, JM Llibre, A Esteve, V Dahl, MC Puertas, ... Nature medicine 16 (4), 460-465, 2010 | 656 | 2010 |
| Clinical presentation and virological assessment of confirmed human monkeypox virus cases in Spain: a prospective observational cohort study EJ Tarín-Vicente, A Alemany, M Agud-Dios, M Ubals, C Suñer, A Antón, ... The Lancet 400 (10353), 661-669, 2022 | 532 | 2022 |
| Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: a meta-analysis P Domingo, I Mur, GM Mateo, M del Mar Gutierrez, V Pomar, N de Benito, ... Jama 326 (6), 499-518, 2021 | 476 | 2021 |
| Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a … L Wittkop, HF Günthard, F De Wolf, D Dunn, A Cozzi-Lepri, A De Luca, ... The Lancet infectious diseases 11 (5), 363-371, 2011 | 472 | 2011 |
| Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study N Friis-Møller, R Thiebaut, P Reiss, R Weber, A D'Arminio Monforte, ... European journal of cardiovascular prevention & rehabilitation 17 (5), 491-501, 2010 | 444 | 2010 |
| Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT trials compared with the general population AJ Rodger, R Lodwick, M Schechter, S Deeks, J Amin, R Gilson, ... Aids 27 (6), 973-979, 2013 | 424 | 2013 |
| Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis JZ Li, R Paredes, HJ Ribaudo, ES Svarovskaia, KJ Metzner, MJ Kozal, ... Jama 305 (13), 1327-1335, 2011 | 416 | 2011 |
| Gut microbiota linked to sexual preference and HIV infection M Noguera-Julian, M Rocafort, Y Guillén, J Rivera, M Casadellà, P Nowak, ... EBioMedicine 5, 135-146, 2016 | 397 | 2016 |
| Prospective randomized two-arm controlled study to determine the efficacy of a specific intervention to improve long-term adherence to highly active antiretroviral therapy A Tuldrà, CR Fumaz, MJ Ferrer, R Bayés, A Arnó, M Balagué, A Bonjoch, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 25 (3), 221-228, 2000 | 346 | 2000 |
| A neutralizing monoclonal antibody for hospitalized patients with Covid-19 Activ-3/Tico Ly-CoV555 Study Group New England Journal of Medicine 384 (10), 905-914, 2021 | 334 | 2021 |
| Update of the drug resistance mutations in HIV-1: March 2013 VA Johnson, V Calvez, HF Günthard, R Paredes, D Pillay, RW Shafer, ... Topics in antiviral medicine 21 (1), 6, 2013 | 325 | 2013 |
| Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: results from the EuroSIDA study R Paredes, A Mocroft, O Kirk, A Lazzarin, SE Barton, J Van Lunzen, ... Archives of internal medicine 160 (8), 1123-1132, 2000 | 293 | 2000 |
Bonaventura ClotetDirector irsiCaixa AIDS Research Institute在 irsicaixa.es 的电子邮件经过验证
